Fabrication of a paper-based colorimetric molecular test for SARS-CoV-2

Wang, Jiangshan; Dextre, Andres; Pascual-Garrigos, Ana; Davidson, Josiah Levi; McChesney, Darby; Seville, Jordan; Verma, Mohit S.

doi:10.1016/j.mex.2021.101586

Cited by 21 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the absence of pharmaceutical interventions initially, many nations resorted to population-wide lockdowns to minimise the spread of the virus and allow their health systems to cope [ 4 ]. Concurrently, rapid detection of SARS-CoV-2 virus by real-time RT-PCR [ 5 ], RT-LAMP [ 6 , 7 ] and antigen tests [ 8 ] were widely adopted to enable case finding and contact tracing. In the year 2020, a provisional data analysis conducted by WHO in 84 countries indicated a 21% shortfall in TB case notifications compared to 2019 due to the COVID-19 pandemic; this was even 28% for the 10 high TB-burden countries.…”

Section: Introductionmentioning

confidence: 99%

Performance of WHO-Endorsed Rapid Tests for Detection of Susceptibility to First-Line Drugs in Patients with Pulmonary Tuberculosis in Bangladesh

et al. 2022

View full text Add to dashboard Cite

The fast and accurate detection of susceptibility in drugs is a major challenge for a successful tuberculosis (TB) control programme. This study evaluated the performance of WHO-endorsed rapid diagnostic tools, such as BACTEC MGIT 960 SIRE (MGIT SIRE), GenoType MTBDRplus (MTBDRplus) and Xpert MTB/RIF (Xpert), for detecting susceptibility to first-line anti-TB drugs among pulmonary TB patients in Bangladesh. A total of 825 sputum samples with results from drug susceptibility testing (DST) against first-line anti-TB drugs in the MGIT SIRE, MTBDRplus and Xpert assays were evaluated and compared with the gold standard proportion susceptibility method of the Lowenstein–Jensen (LJ) medium. The overall sensitivities of MGIT SIRE were 97.6%, 90.0%, 61.3% and 44.9%, while specificities were 89.9%, 94.5%, 91.3% and 92.2% for detection of susceptibility to isoniazid (INH), rifampicin (RIF), streptomycin (STR) and ethambutol (EMB), respectively. For MTBDRplus, the sensitivities were 88.0% and 88.7%, and the specificities were 97.4% and 97.8% for the detection of susceptibility to INH and RIF, respectively. Xpert demonstrated a sensitivity and specificity of 94.8% and 99.5%, respectively, for the detection of RIF susceptibility. All tests performed significantly better in retreated TB patients compared with primary TB cases. For detection of RIF and INH susceptibility, all three assays showed almost perfect agreement with the LJ method, although MGIT SIRE exhibited low agreement for STR and EMB. Considering the high performance, shorter turnaround time and ease of use, molecular-based approaches Xpert and MTBDRplus can be widely implemented throughout the country for the rapid detection of drug-resistant TB.

show abstract

Section: Introductionmentioning

confidence: 99%

Performance of WHO-Endorsed Rapid Tests for Detection of Susceptibility to First-Line Drugs in Patients with Pulmonary Tuberculosis in Bangladesh

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This might be due to the different methods used for quantifying the template concentration (e.g., UV meter, fluorometer, droplet digital PCR) or from the assay composition itself. It has been demonstrated that different reagent compositions or even primer sets will influence the assay’s sensitivity [ 83 , 119 ]. Dong et al comparatively evaluated 19 sets of LAMP primers targeting different genomic regions of SARS-CoV-2 [ 116 ].…”

Section: Detection Methodsmentioning

confidence: 99%

“…In addition, to achieve optimal performance, uniform rehydration of the reagents is required for the paper-based biosensor. Various preservatives, paper materials, and drying techniques were tested, but no consensus was reached on which procedure or composition might be ideal [ 73 , 83 , 97 , 119 , 127 ]. By overcoming these challenges, “cold-chain storage” could be eliminated to increase the convenience and decrease the costs associated with detection devices.…”

Section: Detection Methodsmentioning

confidence: 99%

Paper-Based Biosensors for the Detection of Nucleic Acids from Pathogens

et al. 2022

Self Cite

View full text Add to dashboard Cite

Paper-based biosensors are microfluidic analytical devices used for the detection of biochemical substances. The unique properties of paper-based biosensors, including low cost, portability, disposability, and ease of use, make them an excellent tool for point-of-care testing. Among all analyte detection methods, nucleic acid-based pathogen detection offers versatility due to the ease of nucleic acid synthesis. In a point-of-care testing context, the combination of nucleic acid detection and a paper-based platform allows for accurate detection. This review offers an overview of contemporary paper-based biosensors for detecting nucleic acids from pathogens. The methods and limitations of implementing an integrated portable paper-based platform are discussed. The review concludes with potential directions for future research in the development of paper-based biosensors.

show abstract

“…The device only needs a simple heat source to carry out the experiment it does not need to extract and concentrate RNA in advance, and the results can be obtained by observing the colorimetric response with the naked eye. Therefore, it is very suitable for areas with limited resources [113]. Farshidfar formulated a smartphone-based microfluidic system for the detection of the COVID-19 virus in saliva that facilitates the early diagnosis of COVID-19 [114].…”

Section: Application Of Infectious Disease Detectionmentioning

confidence: 99%

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Yang

Zhang

et al. 2022

Sensors

104

View full text Add to dashboard Cite

The early diagnosis of infectious diseases is critical because it can greatly increase recovery rates and prevent the spread of diseases such as COVID-19; however, in many areas with insufficient medical facilities, the timely detection of diseases is challenging. Conventional medical testing methods require specialized laboratory equipment and well-trained operators, limiting the applicability of these tests. Microfluidic point-of-care (POC) equipment can rapidly detect diseases at low cost. This technology could be used to detect diseases in underdeveloped areas to reduce the effects of disease and improve quality of life in these areas. This review details microfluidic POC equipment and its applications. First, the concept of microfluidic POC devices is discussed. We then describe applications of microfluidic POC devices for infectious diseases, cardiovascular diseases, tumors (cancer), and chronic diseases, and discuss the future incorporation of microfluidic POC devices into applications such as wearable devices and telemedicine. Finally, the review concludes by analyzing the present state of the microfluidic field, and suggestions are made. This review is intended to call attention to the status of disease treatment in underdeveloped areas and to encourage the researchers of microfluidics to develop standards for these devices.

show abstract

Fabrication of a paper-based colorimetric molecular test for SARS-CoV-2

Cited by 21 publications

References 7 publications

Performance of WHO-Endorsed Rapid Tests for Detection of Susceptibility to First-Line Drugs in Patients with Pulmonary Tuberculosis in Bangladesh

Performance of WHO-Endorsed Rapid Tests for Detection of Susceptibility to First-Line Drugs in Patients with Pulmonary Tuberculosis in Bangladesh

Paper-Based Biosensors for the Detection of Nucleic Acids from Pathogens

Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges

Contact Info

Product

Resources

About